Product Description
PDHK inhibitor; Decreases blood glucose by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism. (Sourced from: https://www.akrospharma.com/pipeline-products/pipe/)
Mechanisms of Action: PDK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Akros Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Heart Failure, Chronic|Heart Failure, Systolic
Phase 1: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
RELIEF-PAH | P2 |
Withdrawn |
Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension |
2021-03-01 |
23% |
BEAT-CHF | P2 |
Terminated |
Heart Failure, Chronic|Heart Failure, Systolic |
2019-04-29 |
|
AT251-U-13-001 | P1 |
Completed |
Type 2 Diabetes |
2014-08-01 |